Skip to main content
19279 search results for:

Acute Myeloid Leukemia 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-04-2024 | Online First

    CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment

    Mutations in CCAAT enhancer binding protein α (CEBPA) occur in approximately 10% of patients with de novo acute myeloid leukemia (AML). Emerging evidence supports that in-frame mutations in the basic leucine zipper domain of CEBPA (CEBPAbZIP−inf) …

  2. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    Venous thromboembolism in patients with acute myeloid leukemia: development of a predictive model

    Thrombosis is one of the most prominent causes of morbidity and mortality among patients with cancer [ 1 – 4 ]. The risk of thrombosis in acute leukemias might be similar to or even higher than the risk for those with solid neoplasms and varies …

  3. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    A chest CT-based nomogram for predicting survival in acute myeloid leukemia

    Acute myeloid leukemia (AML) is the common hematological malignancy comprising approximately 15% of leukemia cases. AML is driven by a series of genetic and epigenetic events, with induction chemotherapy and hematopoietic stem cell transplantation …

  4. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation

    This study aims to investigate the role and mechanism of tubiquitin-conjugating enzyme E2 C (UBE2C) in acute myeloid leukemia (AML). Initially, UBE2C expression in leukemia was analyzed using the Cancer Genome Atlas database. Further, we silenced …

  5. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    T cell-mediated tumor killing sensitivity gene signature-based prognostic score for acute myeloid leukemia

    Acute myeloid leukemia (AML) refers to heterogenous hematopoetic neoplasms that are well defined and may occur spontaneously or secondarily in response to chemoradiotherapy for other malignancies [ 1 ]. Although rare, with incidence rates ranging …

  6. 14-03-2024 | Acute Myeloid Leukemia | OriginalPaper

    JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML)

  7. 27-04-2024 | Online First

    GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy

    Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy. Cytarabine (Ara-C)-based chemotherapy is the primary treatment for AML, but currently known prognostic risk stratification factors cannot fully explain the individual …

  8. 17-04-2024 | Digoxin | Online First

    Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia

    De novo acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) have worse treatment outcomes. Arsenic trioxide (ATO) used in the treatment of acute promyelocytic leukemia (APL) has been …

  9. 05-04-2024 | Tumor Lysis Syndrome | Online First

    Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era

    Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction …

  10. 23-03-2024 | Acute Myeloid Leukemia | Online First

    XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway

    Acute myeloid leukemia (AML) patients with DNA methyltransferase 3A (DNMT3A) mutation display poor prognosis, and targeted therapy is not available currently. Our previous study identified increased expression of Exportin1 (XPO1) in DNMT3AR882H …

  11. Open Access 01-12-2024 | Letter

    A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia

    Although killer Ig-like receptor ligands (KIR-L) mismatch has been associated with alloreactive natural killer cell activity and potent graft-versus-leukemia (GVL) effect among adults with acute myeloid leukemia (AML), its role among children with …

  12. 01-05-2024 | Pegfilgrastim | OriginalPaper

    Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients

    Acute myeloid leukemia (AML) is an aggressive malignancy requiring intensive chemotherapy to achieve durable responses. The cornerstone treatment consists of induction chemotherapy, including the combination of cytarabine and an anthracycline …

  13. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    A novel immunogenic cell death-related classification indicates the immune landscape and predicts clinical outcome and treatment response in acute myeloid leukemia

    Acute myeloid leukemia (AML) is a hematological tumor with malignant proliferation of hematopoietic stem cells [ 1 ]. AML is heterogeneous due to complex acquired somatic mutations and genomic mutations [ 2 ]. Although new targeted drugs have made …

  14. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia

    Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. The current risk stratification system is essential but remains insufficient to select the best schedules. Cysteine-rich protein 1 (CSRP1) is a member of the CSRP …

  15. 22-03-2024 | Acute Myeloid Leukemia | Online First

    Transient Spontaneous Remission of Acute Myeloid Leukemia with Mutated RUNX1: A Rare Report

  16. 09-03-2024 | Overweight | Online First

    Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study

    The dosage of chemotherapy drugs for overweight/obese children with acute myeloid leukemia (AML) has been empirically reduced based on ideal body weight (BW) in Japan to reduce the risk of adverse events. We investigated the associations between …

  17. Open Access 01-12-2024 | Acute Myeloid Leukemia | OriginalPaper

    PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model

    Acute myeloid leukemia (AML) is a malignant hematologic disease caused by gene mutations and genomic rearrangements in hematologic progenitors. The PHF6 (PHD finger protein 6) gene is highly conserved and located on the X chromosome in humans and …

  18. 01-04-2024 | Gilteritinib | OriginalPaper

    Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report

    Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA …

  19. Open Access 01-03-2024 | Acute Myeloid Leukemia | OriginalPaper

    Pan-cancer analysis of DDIT4 identifying its prognostic value and function in acute myeloid leukemia

    The incidence of AML is approximately 4.1 per 100,000 women and men per year. The mortality rate of AML is 2.7 per 100,000 per year (2021). AML is a genetically heterogenous blood tumor, characterized by the uncontrolled clonal overexpansion of …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.